Dear All, BARDA is interested in hearing from antibiotic developers about antibiotics which could be used under Emergency Use Authorization (EUA) or marketing authorization for the treatment and/or PEP (post-exposure prophylaxis) of a biothreat indication, specifically: Y. pestis, F. tularensis, and/or B. pseudomallei. Here’s the core message from the pre-solicitation notice: Topline: “The U.S. Government

Dear All, Building on the ATLAS database (link) that provides open access to data from 2004 to the present out of the multiple surveillance programs that Pfizer has run over that interval, Wellcome Trust and Pfizer have just announced that the underlying database will also be used to support SPIDAAR (Surveillance Partnership to Improve Data

Dear All, During the 18-19 Nov 2019 FDA-IDSA-NIAID-Pew workshop on ways to enhance antibacterial research (link), we spent some time discussing the slow pace of updates to most guidelines. With the notable exception of the rapid guidance updates used in the HCV community (link), most guidelines are updated infrequently and each update feels like a Herculean